Helsinki, August 2025 — MVision AI announces that Dose+ has received market approval for the Australian market from the Therapeutic Goods Administration (TGA). The product is now available for clinical use across Australia.
Dose+ is an AI-powered dose prediction solution designed to support fast, consistent, and personalised therapy planning for prostate and pelvic lymph node radiation therapy. By predicting achievable VMAT-style dose distributions from CT and RT structures in a single DICOM send, Dose+ provides a personalised starting point for plan optimisation. The predicted 3D dose can be imported into any treatment planning system, enabling personalised planning and higher automation while maintaining high plan quality.
Dose+ features two specialised AI models for male pelvic radiotherapy, clinically validated across multiple institutions. The prostate model supports treatment planning for localised disease, while the pelvic LN model assists in cases with lymph node involvement. Both models support standard and moderate fractionation schedules, including simultaneous integrated boost techniques.
“Achieving TGA approval for Dose+ is an important milestone for us,” said Mahmudul Hasan, Founder and Executive Director of MVision AI. “By providing AI-guided dose prediction, we are helping radiation oncology teams improve efficiency and personalisation in treatment planning while maintaining high plan quality.”
MVision AI continues its partnership with alphaXRT, its distributor for Australia and New Zealand, to support the adoption of Dose+ across clinics and hospitals in the region.
For more information about Dose+, visit www.mvision.ai/dose or contact info@mvision.ai.
About MVision AI
MVision AI is a leading provider of AI-powered solutions for radiation therapy treatment planning. Our mission is to empower radiation oncology professionals with cutting-edge technology to streamline workflows, enhance treatment quality, and facilitate more patient-focused care. With a commitment to innovation and excellence, MVision AI continues to advance cancer care through the power of AI.